{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'EOT visit is the last visit during the treatment phase before subjects begin the Post', 'Treatment Follow Up and/or Survival Follow Up phase. The reason(s) for the', 'discontinuation from study treatment will be recorded and assessments will be performed', 'per Appendix C, Study Activities.', 'Disease/Response Assessment, CT/MRI of the brain (if applicable), and submission of', 'scans to the CRAC, may be omitted if performed within the last 6 weeks.', 'Post-Treatment Follow Up', 'For all subjects who discontinue study treatment for reasons other than disease', 'progression, the first follow-up visit will occur at 6 weeks (= 1 week) after the last', 'Disease Response/Assessment, then every 6 weeks (= 1 week) until disease progression or', 'initiation of new anti-cancer therapy, whichever occurs first. Refer to Appendix C, Study', 'Activities for details of required assessments.', 'At disease progression, an optional collection of fresh tumor material may be conducted', '(Section 5.3.1.2, Collection and Handling of Biomarker and Optional Exploratory', 'Research has details regarding Tumor Material at Time of Disease Progression).', 'Survival Follow Up (OS)', 'After disease progression or if subjects stop treatment and decline further study', 'radiographic assessments prior to the endpoint of disease progression, subjects will be', 'followed for subsequent anti-cancer therapies (dates and responses), as well as survival', 'status, every 6 weeks* (= 1 week) until the endpoint of death, the subject becomes lost to', 'follow-up or withdraws consent, or termination of the study by AbbVie, whichever occurs', 'first (*or as requested by AbbVie to support data analysis). If the subject withdraws from', 'study follow-up, the study staff may use a public information source (such as county', 'records) to obtain information about survival status only, as appropriate per local', 'regulations. Refer to Appendix C, Study Activities for details of required assessments.', '54']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.1.2', 'Collection and Handling of Biomarker and Optional', 'Exploratory Research Samples', 'Biomarker Samples', 'Blood, tumor material, and serosal fluid will be collected as noted in Appendix C, Study', 'Activities and may be utilized to evaluate known and/or novel markers (nucleic acids,', 'peptides/proteins and/or metabolites) of disease status, related conditions or to evaluate', 'the association with pharmacokinetics, safety or efficacy. Samples will also be utilized', 'for the development of Companion Diagnostics in conjunction with rovalpituzumab', 'tesirine clinical development. The biomarker rationale is discussed in the Biomarker', 'Research Variables Section (Section 5.3.6).', 'All biomarker samples should be labeled and shipped as outlined in the study-specific', 'laboratory manual.', 'AbbVie (or people or companies working with AbbVie) will store the samples in a secure', 'storage space with adequate measures to protect confidentiality. The samples may be', 'retained while research on rovalpituzumab tesirine (or drugs of this class) or this disease', 'and related conditions continues, but for no longer than 20 years after study completion,', 'or per local requirement.', 'Tumor Material at Screening', 'For all subjects, tumor material representative of the qualifying malignancy must be', 'submitted to a central laboratory for determination of DLL3 expression. An archived', 'tumor specimen or fresh tumor material (obtained via on-study biopsy procedure if', 'archival tumor specimen is unavailable) may be used for DLL3 expression evaluation by', 'methods such as but not necessarily limited to immunohistochemistry (IHC). Additional', 'analyses, such as routine hematoxylin and eosin for morphology, IHC for confirmation of', 'diagnosis (e.g., for synaptophysin, chromogranin-A, or CD56), or scoring of immune', 'infiltrates (e.g., IHC for CD3+, CD4+, CD8+, and Foxp3+ cells) may be performed.', '55']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Material may also be utilized for exploratory biomarkers research of drug sensitivity,', 'resistance, or disease biology.', 'Blood (Plasma) for Inflammatory Markers and Circulating Tumor DNA (ctDNA)', 'At the indicated times noted in Appendix C, Study Activities, blood will be collected,', 'processed to plasma for testing of inflammatory markers including erythrocyte', 'sedimentation rate (ESR), C-reactive protein (CRP), antinuclear antibodies (ANA),', 'rheumatoid factor (RF), and ctDNA. On Day 1 (-3 day window is permitted) of each', 'cycle, the collection will be pre-infusion. A sample will also be collected at the EOT or at', 'the time of disease progression.', 'Blood (Serum) for Tumor and Soluble Markers', 'At the indicated times noted in Appendix C, Study Activities, blood will be collected,', 'processed as serum for possible testing of tumor-specific biomarkers that may reflect', 'disease burden such as but not necessarily limited to neuron-specific enolase (NSE) and', 'biomarkers that may be related to the pharmacodynamics effects of rovalpituzumab', 'tesirine such as but not necessarily limited to soluble DLL3, circulating chemokines, or', 'cytokines such as vascular endothelial growth factor (VEGF), epidermal growth factor', '(EGF), interleukin (IL)-6, or IL-8. Other biomarkers based on emerging science may also', 'be assessed. On Day 1 (-3 day window is permitted) of each cycle, the collection will be', 'pre-infusion. A sample will also be collected at the EOT or at the time of disease', 'progression.', 'Blood for Circulating Tumor Cells', 'At the indicated times noted in Appendix C, Study Activities, blood samples will be', 'collected for assessment and characterization of circulating tumor cells (CTCs) as a', 'possible reflection of disease burden and DLL3 expression to study association with', 'efficacy. Whole blood sample will be collected for CTC analysis at pre-dose on Cycle 1', 'Day 1 (-3 days window is permitted) and EOT only at specific sites based on feasibility.', '56']\n\n###\n\n", "completion": "END"}